IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
IAI Accepts, published online ahead of print on 12 February 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
IAI.01606-06v1
75/5/2152    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baron, S. D.
Right arrow Articles by Metzger, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baron, S. D.
Right arrow Articles by Metzger, D. W.
Infect. Immun. doi:10.1128/IAI.01606-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Inactivated Francisella tularensis LVS Protects Against Respiratory Tularemia By Intranasal Vaccination in an IgA-Dependent Fashion

Shawn D. Baron, Rajendra Singh, and Dennis W. Metzger*

Center for Immunology & Microbial Disease, Albany Medical College, Albany, NY 12208

* To whom correspondence should be addressed. Email: metzged{at}mail.amc.edu.


   Abstract

Francisella tularensis is a gram-negative intracellular bacterium that is considered to be a potential category A biological weapon due to its extreme virulence. Although vaccination with the attenuated Live Vaccine Strain (LVS) of F. tularensis can protect against lethal challenge, use of inactivated or subunit forms as vaccine candidates for induction of protective antibody responses has not been fully evaluated. In the present study, we tested whether immune protection in the lung could be stimulated by intranasal administration of inactivated LVS together with IL-12 as an adjuvant. LVS was inactivated by heat, paraformaldehyde treatment or exposure to UV, and inactivation of the preparations was confirmed by assessing bacterial growth and survival of mice after direct inoculation. It was found that mucosal vaccination with inactivated LVS provided 90-100% protection to mice after lethal intranasal challenge with 104 CFU of LVS, and this protection was dependent upon inclusion of exogenous IL-12 during vaccine administration. Survival of vaccinated mice after live bacterial challenge was correlated with reduced bacterial burden, decreased pulmonary inflammation, increased serum antibody titers and lower levels of IFN-gamma, TNF-alpha, and IL-6 in lungs, livers and spleens. Whereas NK cells were primarily responsible for the production of IFN-gamma in unvaccinated, challenged animals, vaccinated mice showed increased levels of lung IFN-gamma+ CD4+ T cells after challenge. Significantly, mice genetically deficient in IgA expression were unable to survive lethal challenge after vaccination. These results are the first to demonstrate IgA-mediated protection against lethal respiratory tularemia by mucosal vaccination with inactivated F. tularensis LVS.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2007 by the American Society for Microbiology. All rights reserved.